Houston needs to lighten up a little, sheesh. Photo by Rome Wilkerson on Unsplash

Not-so-happy news for Texans living in Houston – they're living in one of the "unhappiest" cities in the nation.

A recent SmartAsset study ranked Houston the No. 81 happiest city in the U.S., based on an analysis of 90 large cities for their residents' quality of life, well being, and personal finances.

The city's rank in the bottom 10 — alongside Texas neighbors Dallas (No. 80), El Paso (No. 83), and Laredo (No. 89) – shows not everything about Houston is as easygoing as people think it is. We can hear Ken Hoffman's disagreement from here.

The study found 28.5 percent of all Houston households make a six-figure salary or more, and 16.2 percent of residents are burdened by their housing costs. Houston's poverty rate is 20.7 percent, so maybe it really is more difficult to live comfortably in the city, after all.

Houston has a marriage rate of 39.4 percent, and its residents have a life expectancy of 79 years old. Nearly 76 percent of residents have health insurance, and a Houstonian has nearly five "mentally unhealthy" days per month on average.

Our beloved city has had some bad press recently: H-Town isn't exactly revered for having the best drivers; the city and its suburbs are apparently less appealing for new residents making the move to Texas; and its popularity in the tech industry seems to be waning.

It's not all doom and gloom, though. There's always plenty of new restaurants to try, our city's inventive art scene remains unmatched, and plenty of hometown hero celebrities, Hall of Fame athletes, and talented musicians praise Houston for its culture and hospitality.

While money can't necessarily buy happiness, SmartAsset suggests that having a higher quality of life can influence a person's financial decisions, therefore leading to a greater probability of beneficial outcomes. Of course, that's assuming high financial literacy and strong money management skills.

"Depending where you live, certain quality of life factors, including metrics like life expectancy, infrastructure and the rate of marriage, can ultimately impact your happiness," the report's author wrote.

Elsewhere in Texas, the Dallas suburb of Plano soared to the top as the No. 2 happiest city in the nation. More than half (52.5 percent) of all Plano households make a six-figure salary or more, and only 12.1 percent of residents are burdened by their housing costs. Plano's poverty rate is less than five percent, its marriage rate is 56 percent, and nearly 90 percent of Plano residents have health insurance.

Other Texas cities that earned spots in the report, that notably aren't as happy as Plano, include: Fort Worth (No. 38), Arlington (No. 47), Irving (No. 64), Austin (No. 65), San Antonio (No. 70), Corpus Christi (No. 77), and Lubbock (No. 78).

The top 10 happiest cities in the U.S. are:

  • No. 1 – Arlington, Virginia
  • No. 2 – Plano, Texas
  • No. 3 – Fremont, California
  • No. 4 – San Jose, California
  • No. 5 – Seattle, Washington
  • No. 6 – Boise City, Idaho
  • No. 7 – Raleigh, North Carolina
  • No. 8 – Chesapeake, Virginia
  • No. 9 – San Francisco, California
  • No. 10 – Anchorage, Alaska
The report ranked the 90 most populous U.S. cities based on data from the U.S. Census Bureau 1-Year American Community Survey for 2022 and from the County Health Rankings and Roadmaps for 2023. Data that factored into each city's ranking included a city's household income, poverty level, life expectancy, health insurance rates, marriage rates, overcrowding rates, and more.The full report and its methodology can be found on smartasset.com

.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”